Acelyrin, Inc. (NASDAQ:SLRN) Shares Sold by Ausdal Financial Partners Inc.

Ausdal Financial Partners Inc. cut its holdings in shares of Acelyrin, Inc. (NASDAQ:SLRN) by 33.7% during the fourth quarter, HoldingsChannel.com reports. The firm owned 12,800 shares of the company’s stock after selling 6,500 shares during the period. Ausdal Financial Partners Inc.’s holdings in Acelyrin were worth $40,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Geode Capital Management LLC grew its stake in Acelyrin by 30.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,651,614 shares of the company’s stock worth $8,144,000 after buying an additional 388,631 shares during the last quarter. State Street Corp increased its holdings in shares of Acelyrin by 10.0% during the third quarter. State Street Corp now owns 1,273,096 shares of the company’s stock valued at $6,276,000 after acquiring an additional 116,094 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Acelyrin by 81.4% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 609,678 shares of the company’s stock valued at $3,006,000 after purchasing an additional 273,604 shares during the last quarter. Point72 Asset Management L.P. boosted its stake in Acelyrin by 566.7% in the 3rd quarter. Point72 Asset Management L.P. now owns 250,300 shares of the company’s stock worth $1,234,000 after purchasing an additional 212,758 shares in the last quarter. Finally, Franklin Resources Inc. grew its position in Acelyrin by 36.9% during the 3rd quarter. Franklin Resources Inc. now owns 128,591 shares of the company’s stock worth $634,000 after purchasing an additional 34,642 shares during the last quarter. Hedge funds and other institutional investors own 87.31% of the company’s stock.

Insider Activity

In related news, CEO Mina Kim sold 17,986 shares of the firm’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $2.74, for a total transaction of $49,281.64. Following the sale, the chief executive officer now owns 671,753 shares in the company, valued at approximately $1,840,603.22. This trade represents a 2.61 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 13.60% of the company’s stock.

Acelyrin Price Performance

NASDAQ SLRN opened at $2.60 on Friday. The company has a fifty day moving average of $2.34 and a 200 day moving average of $3.75. The company has a market capitalization of $261.85 million, a PE ratio of -1.06 and a beta of 1.27. Acelyrin, Inc. has a 1 year low of $1.85 and a 1 year high of $7.25.

Acelyrin (NASDAQ:SLRN) last posted its earnings results on Wednesday, March 19th. The company reported ($0.79) EPS for the quarter, topping the consensus estimate of ($0.86) by $0.07. Research analysts expect that Acelyrin, Inc. will post -2.53 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have issued reports on SLRN shares. Citigroup decreased their price target on shares of Acelyrin from $6.00 to $3.00 and set a “neutral” rating for the company in a report on Tuesday, January 7th. Wells Fargo & Company lowered their price target on Acelyrin from $15.00 to $13.00 and set an “overweight” rating for the company in a research report on Wednesday, December 11th. Finally, HC Wainwright cut their price objective on Acelyrin from $8.00 to $6.00 and set a “neutral” rating on the stock in a report on Tuesday, January 7th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $9.60.

About Acelyrin

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.